Hermes Investment Management Ltd. Invests $611,000 in Zimmer Biomet Holdings, Inc. (ZBH)

Hermes Investment Management Ltd. bought a new stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) during the second quarter, according to its most recent filing with the SEC. The institutional investor bought 4,762 shares of the medical equipment provider’s stock, valued at approximately $611,000.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Parkside Financial Bank & Trust increased its stake in Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock valued at $102,000 after buying an additional 22 shares in the last quarter. Parallel Advisors LLC increased its stake in Zimmer Biomet Holdings by 20.8% in the first quarter. Parallel Advisors LLC now owns 1,157 shares of the medical equipment provider’s stock valued at $138,000 after buying an additional 199 shares in the last quarter. IHT Wealth Management LLC increased its stake in Zimmer Biomet Holdings by 28.4% in the first quarter. IHT Wealth Management LLC now owns 1,158 shares of the medical equipment provider’s stock valued at $139,000 after buying an additional 256 shares in the last quarter. Sandy Spring Bank increased its stake in Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock valued at $149,000 after buying an additional 20 shares in the last quarter. Finally, Ledyard National Bank increased its stake in Zimmer Biomet Holdings by 9.3% in the first quarter. Ledyard National Bank now owns 1,293 shares of the medical equipment provider’s stock valued at $157,000 after buying an additional 110 shares in the last quarter. 82.84% of the stock is currently owned by hedge funds and other institutional investors.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) opened at 113.08 on Thursday. The company has a 50 day moving average of $123.56 and a 200 day moving average of $121.24. The company has a market capitalization of $22.86 billion, a PE ratio of 32.21 and a beta of 1.20. Zimmer Biomet Holdings, Inc. has a 52-week low of $95.63 and a 52-week high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $2.08 earnings per share for the quarter, missing the Zacks’ consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The firm had revenue of $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. During the same period in the previous year, the firm posted $2.02 earnings per share. The company’s quarterly revenue was up 1.1% compared to the same quarter last year. On average, equities research analysts forecast that Zimmer Biomet Holdings, Inc. will post $8.24 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 27th. Stockholders of record on Friday, September 22nd will be paid a $0.24 dividend. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.85%. Zimmer Biomet Holdings’s payout ratio is presently 27.59%.

TRADEMARK VIOLATION WARNING: This piece was first published by BBNS and is the property of of BBNS. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://baseballnewssource.com/markets/hermes-investment-management-ltd-invests-611000-in-zimmer-biomet-holdings-inc-zbh-updated-updated/1314243.html.

Several research analysts have issued reports on ZBH shares. Wells Fargo & Company lowered shares of Zimmer Biomet Holdings from an “outperform” rating to a “market perform” rating in a report on Friday, April 28th. Needham & Company LLC raised their price target on shares of Zimmer Biomet Holdings from $151.00 to $153.00 and gave the stock a “strong-buy” rating in a report on Friday, April 28th. Oppenheimer Holdings, Inc. set a $132.00 price objective on shares of Zimmer Biomet Holdings and gave the company a “buy” rating in a research note on Friday, April 28th. Canaccord Genuity reiterated a “buy” rating on shares of Zimmer Biomet Holdings in a research note on Friday, April 28th. Finally, Goldman Sachs Group, Inc. (The) started coverage on shares of Zimmer Biomet Holdings in a research note on Tuesday, May 16th. They issued a “sell” rating and a $92.00 price objective for the company. Four research analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Zimmer Biomet Holdings currently has an average rating of “Hold” and an average price target of $136.90.

In related news, VP Tony W. Collins sold 16,986 shares of Zimmer Biomet Holdings stock in a transaction on Monday, July 31st. The stock was sold at an average price of $121.74, for a total value of $2,067,875.64. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Sang Yi sold 17,731 shares of Zimmer Biomet Holdings stock in a transaction on Monday, June 12th. The shares were sold at an average price of $124.56, for a total value of $2,208,573.36. The disclosure for this sale can be found here. Insiders own 1.07% of the company’s stock.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with our FREE daily email newsletter.

 


Latest News

Los Angeles Dodgers Move 50 Games Over .500
Los Angeles Dodgers Move 50 Games Over .500
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Miami’s Giancarlo Stanton Sets Marlins Home Run Record
Bryce Harper Latest Star to Suffer Injury
Bryce Harper Latest Star to Suffer Injury
Chicago Cubs Must Survive Without Willson Contreras
Chicago Cubs Must Survive Without Willson Contreras
Cleveland Indians Acquire Jay Bruce From New York Mets
Cleveland Indians Acquire Jay Bruce From New York Mets
Injury to CC Sabathia Adds to Yankees’ Concerns
Injury to CC Sabathia Adds to Yankees’ Concerns


Leave a Reply

 
© 2006-2017 BBNS.